These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36163330)

  • 21. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study.
    Lemaitre RN; Psaty BM; Heckbert SR; Kronmal RA; Newman AB; Burke GL
    Arch Intern Med; 2002 Jun; 162(12):1395-400. PubMed ID: 12076239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients.
    Ohno T; Kobayashi S; Hayashi M; Sakurai M; Kanazawa I
    J Neurol Sci; 2001 Jan; 182(2):95-7. PubMed ID: 11137513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ARTERIOSCLEROSIS IN PARKINSONISM.
    EADIE MJ; SUTHERLAND JM
    J Neurol Neurosurg Psychiatry; 1964 Jun; 27(3):237-40. PubMed ID: 14175292
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of statin on progression of symptomatic intracranial atherosclerosis.
    Kim HJ; Kim EK; Kwon SU; Kim JS; Kang DW
    Can J Neurol Sci; 2012 Nov; 39(6):801-6. PubMed ID: 23041401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - A systematic review and meta-analysis.
    Pertzov B; Eliakim-Raz N; Atamna H; Trestioreanu AZ; Yahav D; Leibovici L
    Clin Microbiol Infect; 2019 Mar; 25(3):280-289. PubMed ID: 30472427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-Hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins), atherosclerosis and coronary syndromes.
    Blum A; Simsolo C; Hasin Y
    Atherosclerosis; 2004 Jul; 175(1):1-5. PubMed ID: 15186940
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pharmacogenetics and anti-inflammatory effect of HMG-CoA reductase inhibitors].
    Rosendo AB; Dal-Pizzol F; Fiegenbaum M; Almeida Sd
    Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):520-5. PubMed ID: 17684611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Total Daily Physical Activity and the Risk of Parkinsonism in Community-Dwelling Older Adults.
    Oveisgharan S; Yu L; Dawe RJ; Bennett DA; Buchman AS
    J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):702-711. PubMed ID: 31046115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging.
    Huang YC; Chang CH; Tsai YH; Weng HH; Lin LC; Lee JD
    BMJ Open; 2022 Apr; 12(4):e060068. PubMed ID: 35487727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins.
    Casserly I; Topol E
    Lancet; 2004 Apr; 363(9415):1139-46. PubMed ID: 15064035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis.
    Arnaud C; Veillard NR; Mach F
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Apr; 5(2):127-34. PubMed ID: 15853754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statins. Evidence of effectiveness in older patients.
    Nash DT
    Geriatrics; 2003 May; 58(5):35-6, 39-42. PubMed ID: 12756679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current management of symptomatic intracranial stenosis: medical versus endovascular therapy.
    Weigele JB; Taylor RA; Kasner SE
    Curr Atheroscler Rep; 2007 Oct; 9(4):296-304. PubMed ID: 18173957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates, statins, osteoporosis, and atherosclerosis.
    Watts N
    South Med J; 2002 Jun; 95(6):578-82. PubMed ID: 12081213
    [No Abstract]   [Full Text] [Related]  

  • 35. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholesterol lowering, nutrition and stroke prevention.
    Spence JD
    Can J Neurol Sci; 2012 Nov; 39(6):700-1. PubMed ID: 23227574
    [No Abstract]   [Full Text] [Related]  

  • 37. Statins for Primary Prevention in Older Adults-Moving Toward Evidence-Based Decision-Making.
    Singh S; Zieman S; Go AS; Fortmann SP; Wenger NK; Fleg JL; Radziszewska B; Stone NJ; Zoungas S; Gurwitz JH
    J Am Geriatr Soc; 2018 Nov; 66(11):2188-2196. PubMed ID: 30277567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Non-lipid effects of statins in atherosclerosis].
    Lévesque H
    Rev Med Interne; 2004 Nov; 25(11):783-5. PubMed ID: 15501346
    [No Abstract]   [Full Text] [Related]  

  • 39. Potential role of statins in inflammation and atherosclerosis.
    Yoshida M
    J Atheroscler Thromb; 2003; 10(3):140-4. PubMed ID: 14564082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
    Marta-Moreno J; Echeandia C; Oliveros-Cid A; Figuerola A; Mola S
    Rev Neurol; 1998 Nov; 27(159):827-30. PubMed ID: 9859160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.